The European Union has granted CE mark certification to Medtronic's Attain Performa portfolio of quadripolar leads.
Available in various shapes including Dual Cant, S-Shape and Straight, the quadripolar leads feature four electrodes with 16 pacing configurations and are designed with shorter spacing between the two centre electrodes to increase phrenic nerve thresholds and reduce phrenic nerve stimulation (PNS).
Attain Performa leads also include steroid elution on all four electrodes for lower chronic pacing thresholds, which contribute to greater device longevity and reduce the likelihood of PNS.
Using an automated in-office test, VectorExpress technology, the leads provide information on physician-selected pacing configurations in less than three minutes and facilitate in selecting the optimal pacing configuration for stimulating the heart, according to the company.
In addition, the leads are compatible with the company's Viva/Brava Quad cardiac resynchronisation therapy defibrillators (CRT-D), which feature the AdaptivCRT algorithm for improving heart failure patients' response rate to therapy by preserving normal heart rhythms and continuously adapting to patient needs.
Medtronic cardiac rhythm disease management business medical director and heart failure vice president and general manager David Steinhaus said, "Our new quadripolar leads were designed with advancements that help physicians customise care for their heart failure patients so they receive the optimal therapy for their condition."
S Filippo Neri Hospital cardiovascular department director and World Society of Arrhythmias president Massimo Santini said, "This sophisticated new lead family provides physicians with the flexibility needed to effectively navigate diverse patient anatomies and help maintain optimal lead position, which has been proven to improve CRT response."
The company said Attain Performa leads are not approved for sale in the US.
Image: Medtronic corporate headquarters in Fridley, Minnesota, US. Photo: Courtesy of Bobak Ha'Eri.